ARC-12
Phase 1 Completed
94 enrolled
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Phase 1 Terminated
3 enrolled
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Phase 1 Completed
89 enrolled
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Phase 1 Completed
11 enrolled
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Phase 1 Completed
22 enrolled
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Phase 1 Terminated
155 enrolled
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Phase 1 Unknown
36 enrolled
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Phase 1 Completed
180 enrolled
BAY1238097, First in Man
Phase 1 Terminated
8 enrolled
IFNa
Phase 1 Completed
35 enrolled
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled